CLDN4 and cancer: The use of in vitro and in vivo models has demonstrated that targeting CLDN1, CLDN3, CLDN4, CLDN6 and CLDN18.2 consistently reduces tumor burden across a multitude of different cancer types, with specific intra-tumoral accumulation and low rates of AEs.